In summary, we established the clinical relevance of the UHRF1-DNMT1-G9a complex in patients with HB and proved the antitumor effect of dually inhibiting DNMT1 and G9a activity in patient-derived xenograft HB models. The gene discussed is EHMT2; the disease is hemoglobin measurement.